Highlights:
•No difference between multiple sclerosis patients without treatment and healthy people in terms of COVID-19 vaccine response.
•Multiple sclerosis patients on disease-modifying treatment have lower antibody responses than those without treatment.
•mRNA vaccine resulted in a more significant antibody response than an inactivated vaccine in multiple sclerosis patients treated with disease-modifying therapies.
•Fingolimod and ocrelizumab resulted in lower antibody response than other disease-modifying therapies in both vaccine types.
•mRNA vaccine resulted in greater antibody response in all treatment groups except for ocrelizumab